Chemotherapy plus durvalumab in triple negative breast cancer

Bookmark and Share
Published: 4 Jun 2018
Views: 1372
Rating:
Save
Prof Sibylle Loibl - German Breast Cancer Group, Frankfurt, Germany

Prof Loibl speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about results from Gepar Nuevo, a trial of anthracycline chemotherapy with durvalumab as a treatment for patients with triple negative breast cancer.

She outlines the patient cohort and stratification for the trial, and the pCR findings which fell just short of statistical significance, though ORR rates were statistically significant, with the best outcomes from patients who were 'primed' with durvalumab.

Prof Loibl also spoke with ecancer about the Gepar X trial, here.

  • Categories: